Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Indian (NIFTY) Pharma Industry Analysis

UpdatedJun 24, 2026
DataAggregated Company Financials
Companies183
  • 7D3.8%
  • 3M13.1%
  • 1Y12.6%
  • YTD12.5%

The Pharma industry is up 3.8% in the last week, with Sun Pharmaceutical Industries up 3.7%. This means that the industry has gained 13% over the past year. Earnings are forecast to grow by 16% annually.

Industry Valuation and Performance

Has the Indian Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 24 Jun 2026₹23.0t₹4.5t₹642.9b29.8x35.8x5.1x
Fri, 22 May 2026₹22.4t₹4.5t₹635.9b29.3x35.3x5x
Sun, 19 Apr 2026₹20.5t₹4.3t₹621.0b28x33x4.7x
Tue, 17 Mar 2026₹20.3t₹4.3t₹621.2b25.5x32.7x4.7x
Thu, 12 Feb 2026₹20.2t₹4.3t₹616.4b28.3x32.7x4.7x
Sat, 10 Jan 2026₹20.3t₹4.2t₹613.3b28.5x33.1x4.8x
Mon, 08 Dec 2025₹20.6t₹4.2t₹612.9b29x33.6x4.9x
Wed, 05 Nov 2025₹20.3t₹4.1t₹596.1b30.2x34.1x5x
Fri, 03 Oct 2025₹20.0t₹4.1t₹588.1b30.6x34.1x4.9x
Sun, 31 Aug 2025₹20.0t₹4.1t₹589.1b29.6x33.9x4.9x
Tue, 29 Jul 2025₹20.9t₹4.0t₹597.0b32.5x35x5.2x
Thu, 26 Jun 2025₹20.1t₹4.0t₹595.3b32.7x33.8x5.1x
Sat, 24 May 2025₹19.8t₹4.0t₹580.2b31.8x34x4.9x
Mon, 21 Apr 2025₹19.5t₹3.9t₹559.2b28.5x34.8x5x
Wed, 19 Mar 2025₹19.1t₹3.9t₹559.4b28.7x34.1x4.9x
Fri, 14 Feb 2025₹19.3t₹3.9t₹550.6b28.8x35.1x5x
Sun, 12 Jan 2025₹20.5t₹3.8t₹527.0b33.7x38.9x5.4x
Tue, 10 Dec 2024₹20.7t₹3.8t₹526.7b36.2x39.4x5.4x
Thu, 07 Nov 2024₹21.3t₹3.8t₹508.0b39.9x41.9x5.6x
Sat, 05 Oct 2024₹21.4t₹3.7t₹492.6b41.2x43.5x5.7x
Mon, 02 Sep 2024₹21.2t₹3.7t₹492.4b39.8x43x5.7x
Wed, 31 Jul 2024₹19.5t₹3.7t₹461.3b38.2x42.3x5.3x
Fri, 28 Jun 2024₹17.4t₹3.6t₹448.3b33.6x38.8x4.9x
Sun, 26 May 2024₹17.1t₹3.5t₹443.8b33.4x38.5x4.8x
Tue, 23 Apr 2024₹16.6t₹3.5t₹418.9b33.2x39.6x4.8x
Thu, 21 Mar 2024₹16.4t₹3.5t₹418.7b31.8x39.2x4.7x
Sat, 17 Feb 2024₹16.9t₹3.5t₹418.9b33.7x40.4x4.9x
Mon, 15 Jan 2024₹15.7t₹3.4t₹395.3b35.2x39.6x4.6x
Wed, 13 Dec 2023₹14.1t₹3.4t₹395.1b31.3x35.7x4.2x
Fri, 10 Nov 2023₹13.6t₹3.3t₹388.9b30.1x35.1x4.1x
Sun, 08 Oct 2023₹13.1t₹3.3t₹369.9b30.1x35.4x4x
Tue, 05 Sep 2023₹12.9t₹3.3t₹367.0b29.8x35x3.9x
Thu, 03 Aug 2023₹12.7t₹3.2t₹345.8b29.4x36.7x4x
Sat, 01 Jul 2023₹11.7t₹3.2t₹342.4b26.4x34.3x3.7x
Price to Earnings Ratio

34.3x


Total Market Cap: ₹11.7tTotal Earnings: ₹342.4bTotal Revenue: ₹3.2tTotal Market Cap vs Earnings and Revenue0%0%0%
Indian Pharma Industry Price to Earnings3Y Average 36.5x202420252026
Current Industry PE
  • Investors are relatively neutral on the Indian Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PE ratio of 36.5x.
  • The industry is trading close to its 3-year average PS ratio of 4.8x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 23% per year over the last three years.
  • Revenues for these companies have grown 12% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Indian Healthcare industry?

IN Market0.57%
Healthcare3.15%
Pharma3.83%
Pharma3.83%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
SUNPHARMA Sun Pharmaceutical Industries₹1.87k3.7%
+₹161.5b		12.4%PE39x
AUROPHARMA Aurobindo Pharma₹1.53k9.8%
+₹79.1b		38.9%PE25.2x
MANKIND Mankind Pharma₹2.53k7.3%
+₹71.2b		9.6%PE54.6x
LAURUSLABS Laurus Labs₹1.48k7.6%
+₹56.5b		121.2%PE90x
CIPLA Cipla₹1.43k4.4%
+₹48.4b		-4.6%PE29.8x

Latest News

CIPLA
₹1,433.10
Cipla
7D
4.4%
1Y
-4.6%
Narrative Update • Jun 22

CIPLA: Fair Outlook As Respiratory Diagnostics And US Generics Pipeline Evolve

Analysts have marginally reduced their fair value estimate for Cipla, trimming the price target from about ₹1,460 to roughly ₹1,457 as they fine-tune assumptions on long term profit margins and forward P/E multiples, while keeping core growth expectations broadly unchanged. What’s in the News for Cipla Cipla launched Ciposcillo, an advanced oscillometer for early detection of respiratory diseases such as COPD and asthma, built on US FDA cleared technology and approved by India’s CDSCO.
530019
₹973.25
Jubilant Pharmova
7D
-0.9%
1Y
-13.1%
New Narrative • Jun 19

Biologics Capacity And Radiopharma Expansion Will Shape A Steady Longer Term Outlook

Catalysts About Jubilant Pharmova Jubilant Pharmova operates across radiopharma, CDMO sterile injectables, generics, allergy immunotherapy, APIs and discovery services, with a global customer base in healthcare and life sciences. What are the underlying business or industry changes driving this perspective?
LAURUSLABS
₹1,481.00
Laurus Labs
7D
7.6%
1Y
121.2%
Narrative Update • Jun 18

LAURUSLABS: Dividend Moves And Governance Changes Will Shape Future Stock Appeal

Analysts have raised their fair value estimate for Laurus Labs to ₹1,370 from ₹1,270, reflecting updated assumptions around slightly adjusted growth, lower profit margins and a higher future P/E multiple in their latest models. Analyst Commentary Bullish analysts looking at Laurus Labs are focusing on how updated assumptions flow through to valuation, execution expectations and potential growth drivers.
524632
₹29.20
Shukra Pharmaceuticals
7D
-6.3%
1Y
120.9%
500257
₹2,356.55
Lupin
7D
3.5%
1Y
22.1%
SPARC
₹234.92
Sun Pharma Advanced Research
7D
-1.5%
1Y
49.6%
SUNPHARMA
₹1,868.00
Sun Pharmaceutical Industries
7D
3.7%
1Y
12.4%
Narrative Update • Jun 17

SUNPHARMA: Obesity And Diabetes Franchise Will Drive Future Stock Upside

Analysts have kept their price target for Sun Pharmaceutical Industries steady at ₹2,039.91. This reflects unchanged assumptions around revenue growth, profit margin and future P/E in their latest update.
ZYDUSLIFE
₹1,112.20
Zydus Lifesciences
7D
3.1%
1Y
15.3%
Narrative Update • Jun 17

ZYDUSLIFE: Buyback, Rare Disease Expansion And USFDA Updates Will Guide Share Outlook

The latest Narrative Update on Zydus Lifesciences keeps the analyst fair value estimate steady at ₹1,066.50, with unchanged assumptions on discount rate, revenue growth, profit margin and future P/E. Analysts view the existing price target framework as still appropriately reflecting the stock's current risk and return trade off.
ORCHPHARMA
₹989.65
Orchid Pharma
7D
-5.6%
1Y
41.5%
526953
₹1,765.55
Venus Remedies
7D
-5.0%
1Y
309.7%
CONCORDBIO
₹1,317.80
Concord Biotech
7D
-4.1%
1Y
-26.0%
Narrative Update • Jun 15

CONCORDBIO: Slower Earnings Outlook Will Limit Upside Despite Upcoming Dividend

Analysts have trimmed their price target on Concord Biotech from ₹1,319 to ₹1,196, citing adjusted expectations for revenue growth, profit margins, and the future P/E multiple. What's in the News A board meeting is scheduled for May 29, 2026, at 15:00 IST to review the audited standalone and consolidated financial results for Q4 and the full year ended March 31, 2026, along with the related audit reports.
MANKIND
₹2,528.60
Mankind Pharma
7D
7.3%
1Y
9.6%
Narrative Update • Jun 15

MANKIND: Subsidiary Reshuffle And Higher P/E Assumptions Will Support Re Rating

Analysts have raised the price target for Mankind Pharma slightly to ₹3,100 from ₹3,085.68, reflecting updated assumptions regarding a higher future P/E multiple, as well as adjusted expectations for revenue growth, profit margins, and the discount rate. What's in the News Board meeting on May 19, 2026 to review standalone and consolidated audited financial results for the quarter and year ended March 31, 2026, consider realignment of security cover for existing non convertible debentures after redemption of ₹12,50,00,00,000 of NCDs on April 16, 2026, review management changes, and evaluate additional investment in subsidiaries.
506690
₹436.00
Unichem Laboratories
7D
-2.7%
1Y
-26.5%
AUROPHARMA
₹1,534.20
Aurobindo Pharma
7D
9.8%
1Y
38.9%
Narrative Update • Jun 06

AUROPHARMA: Rich P E Assumptions Will Magnify Any Margin Execution Slip

The analyst fair value estimate for Aurobindo Pharma has been revised from ₹1,037.51 to ₹1,118.51, with analysts citing updated assumptions for revenue growth, profit margins, and future P/E as the key drivers behind the change. Analyst Commentary Analysts covering Aurobindo Pharma generally frame the revised fair value estimate in the context of execution on growth plans, the sustainability of margins, and how much investors are willing to pay on a P/E basis.
500660
₹2,397.90
GlaxoSmithKline Pharmaceuticals
7D
8.9%
1Y
-25.7%
500488
₹25,574.00
Abbott India
7D
-2.0%
1Y
-18.8%